top of page

🧬 Genomic Biomarkers Market Set to Reach USD 12.56 Billion by 2034 at a 9.4% CAGR

prajwal79
2 hours ago
6 min read

The global genomic biomarkers market is undergoing a structural shift as healthcare systems, pharmaceutical developers, and diagnostic laboratories move toward targeted precision care. Based on data from Polaris Market Research, the global market was valued at USD 5.60 billion in 2025, is estimated at USD 6.12 billion in 2026, and is projected to reach USD 12.56 billion by 2034, expanding at a 9.4% CAGR from 2026 to 2034. At their core, genomic biomarkers are quantifiable features of DNA and RNA including mutations, copy-number variants, gene fusions, expression profiles, and whole-genome markers such as TMB and MSI that help clinicians and researchers interpret disease presence, disease behavior, and likely response to treatment. Practical examples include BRCA1/2 testing to identify suitable candidates for PARP inhibitor therapy and EGFR mutation testing to guide targeted treatment in non-small cell lung cancer.

Economically and operationally, the genomic biomarkers market encompasses assay kits, reagents, sequencing and PCR instrumentation, bioinformatic software, and laboratory testing services. Across drug development, pharmaceutical and biotechnology sponsors rely on genomic biomarkers for patient stratification and risk reduction during clinical trials. Lower DNA sequencing costs monitored by the NHGRI alongside initiatives aimed at bringing whole-genome sequencing for patients to around USD 1,000 or less are enabling laboratories to offer broader gene panels and blood-based tests while making repeated testing more practical across large hospitals, research centers, and community cancer clinics.

Regionally, North America dominated the genomic biomarkers market with a 38.27% share in 2025, supported by advanced healthcare infrastructure, strong adoption of advanced diagnostic technologies, and growing demand for personalized medicine. Within North America, the U.S. accounted for 82.4% of regional revenue in 2025, propelled by expanded precision medicine and advanced genomic testing. Meanwhile, Asia Pacific is projected to grow fastest during the forecast period at an 11.3% CAGR, driven by rising cancer incidence, strengthening healthcare infrastructure, and greater awareness of genomic testing.

🌐𝐁𝐫𝐨𝐰𝐬𝐞 𝐅𝐮𝐥𝐥 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

🚀 Key Market Growth Drivers


  • 🎯 Precision Oncology and Comprehensive Genomic Profiling (CGP): Clinical care is moving away from single-gene tests toward comprehensive genomic profiling, which evaluates multiple genes simultaneously to guide therapy selection. Platforms such as FoundationOne CDx which analyzes 324 genes and Oncomine Dx Express Test which profiles 46 cancer-related genes illustrate how multi-gene testing expands demand for genomic biomarker testing, sequencing platforms, bioinformatics tools, and laboratory services.

  • 💊 Targeted Therapy Approvals: Rising approvals of targeted cancer therapeutics directly stimulate demand for accurate biomarker identification. In 2025, more than 12 new cancer drugs received FDA approval, with 10 utilizing companion diagnostic testing to identify appropriate patient populations including tests targeting MET, EGFR, and HER2 biomarkers.

  • 🧪 Companion Diagnostic (CDx) Expansion: As therapeutic regimens increasingly depend on molecular profiling, companion diagnostics are playing a larger role in matching patients to specific medications. There were 46 companion diagnostics approved by the FDA in 2025, including new and expanded approvals for IDH1/IDH2 mutation testing in glioma and EGFR exon 20 mutation testing in cancer, creating substantial commercial momentum for diagnostic developers.

  • 🧬 Declining Sequencing Costs and Broader Clinical Access: Falling DNA sequencing expenses and efforts tracked by the NHGRI toward whole-genome sequencing around USD 1,000 or less make extensive gene panels, blood-based assays, and serial testing more feasible across hospitals, research institutions, and community cancer clinics.


⚙️ Key Market Dynamics


  • 🔬 Shift from Single-Gene Assays to Multi-Gene Profiling: While single-gene approaches such as qPCR, digital PCR, and in situ hybridization / FISH remain valuable for targeted or rapid workflows, clinical demand is increasingly pulling laboratories toward next-generation sequencing panels capable of detecting SNVs, indels, CNVs, fusions, TMB, MSI, and HRD.

  • 🧫 Trade-Offs Across Testing Platforms: Different genomic technologies balance scope, turnaround time, and operational complexity in distinct ways. Next-generation sequencing profiles tens to hundreds of genes or whole exomes/genomes and can discover novel variants over days (or next-day on automated systems), but carries higher cost and bioinformatics demands; qPCR and digital PCR deliver fast turnarounds in hours for known mutations or MRD monitoring with narrower target scope; microarray covers thousands of known probes in 1–3 days without detecting unknown variants; and in situ hybridization / FISH confirms tissue amplifications or rearrangements such as HER2 and ALK in 1–2 days with lower throughput.

  • 🏥 Divergent End-Use Momentum: Hospitals and diagnostic labs held the largest end-use share at 38.51%, whereas pharmaceutical and biotechnology end use represents the fastest-growing segment at a 10.1% growth rate, alongside academic and research growing at 9.6% as sponsors integrate biomarker stratification into drug discovery and clinical trials.

  • 🌍 Regional Leadership vs. High-Growth Expansion: North America anchors current market scale with a 38.27% share (led by the U.S. at 82.4% of regional revenue), while Asia Pacific leads anticipated growth velocity at an 11.3% CAGR.


⚖️ Market Challenges and Opportunities


  • 💸 High Test Costs and Uneven Reimbursement: Implementing genomic biomarker assays can be costly, leaving patients without sufficient insurance coverage facing affordability hurdles. Because reimbursement policies vary across regions, uneven coverage continues to restrict patient access to genomic biomarker testing.

  • 📜 Stringent Regulatory Requirements: Genomic assays face rigorous regulatory oversight requiring strong evidence of safety and accuracy, which can elevate compliance costs, lengthen approval timelines, and slow innovation.

  • 🧪 Laboratory Standardization Gaps: Differences in testing protocols, instruments, and procedures across laboratories can create variability in results from the same sample, complicating cross-laboratory comparisons and limiting broader clinical confidence.

  • ✅ Analytical and Clinical Validity Hurdles: Assays must reliably detect genetic alterations (analytical validity) and prove those alterations meaningfully inform medical decisions or treatment response (clinical validity), where detection errors or evidentiary gaps can raise costs and delay market entry.

  • 💻 Complex Data Interpretation: High-throughput genomic testing produces massive, complex datasets, making it challenging to distinguish clinically actionable variants tied to disease or drug response from background genetic variation.

  • 🩸 Liquid Biopsy Growth Opportunity: Liquid biopsy enables blood-based detection of disease-associated genetic mutations, reducing reliance on invasive tissue biopsies while supporting ongoing disease monitoring and treatment decisions.

  • 💊 Pharmacogenomics Beyond Oncology: Expanding pharmacogenomics which examines how genetic makeup influences drug response into non-oncology areas such as cardiovascular and mental health care offers meaningful growth potential for genomic testing.


🌐𝐁𝐫𝐨𝐰𝐬𝐞 𝐅𝐮𝐥𝐥 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

🏢 Market Key Companies

The Polaris Market Research report outlines major market players and provides competitive profiles, recent developments, and strategic benchmarking across leading genomic biomarkers companies, while highlighting commercial opportunities in companion diagnostics, NGS-based profiling, and liquid biopsy for diagnostics firms, pharmaceutical sponsors, and investors. Specific corporate names beyond Foundation Medicine (referenced via FoundationOne CDx and foundationmedicine.com) and Oncomine Dx Express Test (referenced via cdxtests.com) are not individually listed in the available report summary.

🧩 Market Segmentation

By biomarker type, the market is divided into predictive biomarkers which held the largest share at 54.11% in 2025 due to growing use of targeted therapeutics and personalized medicine and prognostic biomarkers. By technology, next-generation sequencing led with 61.87% of the 2025 market share on rising demand for complete genomic profiling, alongside qPCR, digital PCR, microarray, and in situ hybridization / FISH.

The report also segments the genomic biomarkers market by evidence stage, disease indication, end use, and region for 2026–2034. Among disease indications, oncology accounted for the largest share at 45.25% in 2025, while neurological indications are growing at 9.7%. Across end use, hospitals and diagnostic labs led with 38.51%, while pharmaceutical and biotechnology leads growth at 10.1% and academic and research expands at 9.6%. Regionally, North America held 38.27% in 2025 (with the U.S. at 82.4% of regional share), while Asia Pacific is projected to grow at an 11.3% CAGR.

📈 Market Trends


  • 🧬 Multi-Gene Panel Adoption: Laboratories and clinicians are increasingly adopting broader panels such as FoundationOne CDx and Oncomine Dx Express Test to capture multiple actionable biomarkers within a single workflow rather than running isolated single-gene assays.

  • 🎯 Biomarker-Linked Drug Launches: With 10 of more than 12 FDA-approved cancer drugs in 2025 paired with companion diagnostics and 46 companion diagnostics approved overall including tests for IDH1/IDH2 in glioma and EGFR exon 20 in cancer therapeutic approvals and diagnostic testing are tightly coupled.

  • 🩸 Non-Invasive Blood-Based Monitoring: Liquid biopsy workflows are gaining traction as a less invasive alternative to tissue sampling for identifying mutations and tracking disease over time.

  • 🧠 Expansion Into Neurological and Pharmacogenomic Care: While oncology leads at 45.25%, neurological indications are expanding at 9.7%, and pharmacogenomics is extending into cardiovascular and mental health applications.


🔮 Future Outlook

Looking ahead from 2026 to 2034, the genomic biomarkers market is positioned to expand from USD 6.12 billion in 2026 to USD 12.56 billion by 2034 at a 9.4% CAGR, building on its USD 5.60 billion valuation in 2025. Continued targeted therapy approvals, wider companion diagnostic adoption, NGS leadership (61.87% share in 2025), predictive biomarker dominance (54.11% share in 2025), and decreasing sequencing costs will support broader clinical integration. At the same time, sustainable long-term expansion will depend on overcoming high test costs, inconsistent reimbursement, regulatory hurdles, standardization gaps, analytical and clinical validity requirements, and data interpretation complexity while scaling liquid biopsy and pharmacogenomics.



 
 
 

Comments


Stay Informed with Our Latest Articles

500 Terry Francine Street, 6th Floor, San Francisco, CA 94158

bottom of page